Monday, March 20, 2017 9:17:00 PM
I see today AstraZenica (who's facilities are supreme compared to Hospira) received another CRL rejecting a drug and one of the reasons was related to manufacturing.
AZN has been working on their warning letter since last May and they thought they had everything resolved at the end of the year. Evidently not.
I'm not sure if the FDA is stricter right now and that could be possible. I hope that Sandoz is looking elsewhere because even if that takes 6-8 months it might be the best option...
Looking at the stock price you can tell the street isn't giving the 'may' option any credibility.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM